Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Moving towards personalized medicine in MDS

Valeria Santini • 16 Dec 2021
ASH 2021
Myelodysplastic Syndromes

Valeria Santini, MD, University of Florence, Florence, Italy, discusses the future of treatment for patients with myelodysplastic syndromes (MDS), emphasizing that the main paradigm shift will be towards a more personalized system. The findings of several ongoing, large scale clinical trials investigating the combination of hypomethylating agents with novel therapies will likely have a significant impact on the standard of care in MDS. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Valeria Santini

2:57
Imetelstat for LR-MDS: insights from the IMerge trial
Valeria Santini • 11 Dec 2023
2:52
Long-term evaluation of luspatercept in ESA-intolerant/refractory LR-MDS: MEDALIST follow-up study
Valeria Santini • 11 Dec 2023
1:34
Managing adverse events with novel therapies in lower-risk MDS
Valeria Santini • 7 Sep 2023
2:25
Approaching ESA failure in patients with lower-risk MDS
Valeria Santini • 7 Sep 2023

Related Videos

2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
4:25
The challenges with accurately diagnosing and risk-stratifying patients with MDS
Klaus Metzeler • 16 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals